l-asparaginase

L-Asparaginase (L-ASNase) (L-ASNase), a hydrolase that catalyzes the conversion of L-asparagine, used in acute lymphoblastic leukemia treatment.Asparaginase is an enzyme that is used as a medication. As a medication, L-asparaginase is used to treat acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin's lymphoma. It is given by injection into a vein, muscle, or under the skin.

D-Asparagine (H-D-Asn-OH) serves as a nitrogen source for yeast strains and acts as a competitive inhibitor of L-Asparagine hydrolysis with a Ki of 0.24 mM.

ASX-173 is an orally active asparagine synthetase (ASNS) inhibitor with an IC50 of 0.113 μM and a Ki of 0.4 nM. It enhances the anticancer activity of L-Asparaginase (ASNase). When combined with ASNase, ASX-173 disrupts nucleotide synthesis and induces cell cycle arrest, apoptosis (apoptosis), and autophagy (autophagy) in leukemia cells. This combination also slows the growth of OCI-AML2 xenograft tumors. ASX-173 is applicable in research on acute lymphoblastic leukemia, acute myeloid leukemia, colorectal cancer, and other cancers.

GCN2iB is a GCN2 inhibitor. GCN2iB may be useful for the treatment of cancer. The inhibition of GCN2 sensitizes cancer cells with low basal-level expression of asparagine synthetase (ASNS) to the antileukemic agent L-asparaginase (ASNase) in vitro and in vivo.

Sanggenol L, a compound from the root bark of Morus alba, inhibits cell growth and promotes apoptotic cell death in melanoma skin cancer cells through activation of the cysteinyl asparaginase cascade and apoptosis-inducing factors. Sanggenol L has anticancer activity and antiproliferative effects and is used in the study of prostate cancer.